APTARGROUP, INC.
AptarGroup (ATR) reported Q2 2026 total sales of $1.03B, up 6% reported, with adjusted EPS of $1.42 above guidance. Adjusted EBITDA was $213M, down 3%, and margins fell due to mix and operational issues in beauty. Pharma core sales grew 8% excluding emergency medicine destocking. Net debt was $1.2B, leverage 1.49x, and Q3 adjusted EPS guidance is $1.45 to $1.53.
Prieur Marc (Segment President) sold 3,500 shares of APTARGROUP, INC. (ATR) at an average of $136.26 ($136.23–$137.10, $0.48M total) across 2 trades on 2026-08-04.
Tanda Stephan B. (President and CEO) sold 9,838 shares of APTARGROUP, INC. (ATR) at $136.16 ($1.34M total) on 2026-08-03.
Over the past 7 days, alphai's AI scored 1 news story mentioning ATR (APTARGROUP, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ATR coverage spans insider activity, earnings and sector analysis.
In the last 30 days, ATR insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($3.0M). The most active reporter was Prieur Marc, Segment President, with 2 filings.
Earnings call provides fresh quarterly results, margin drivers, and explicit Q3 EPS guidance, setting near-term expectations for ATR.
This is a routine insider open-market sale by a segment president, with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
This is a routine insider open-market sale with no 10b5-1 plan stated; it may slightly affect sentiment but does not change fundamentals by itself.
The filing discloses a same-day insider open-market sale, which can modestly affect near-term sentiment but is not a fundamental catalyst.
Q2 showed revenue growth but margin and EPS pressure, while Q3 guidance implies a modest sequential improvement.
alphai scores every news story that mentions ATR with an AI model for sentiment and relevance, and aggregates insider trades from APTARGROUP, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AptarGroup (ATR) reported Q2 2026 total sales of $1.03B, up 6% reported, with adjusted EPS of $1.42 above guidance. Adjusted EBITDA was $213M, down 3%, and margins fell due to mix and operational issues in beauty. Pharma core sales grew 8% excluding emergency medicine destocking. Net debt was $1.2B, leverage 1.49x, and Q3 adjusted EPS guidance is $1.45 to $1.53.
6 min readPrieur Marc (Segment President) sold 3,500 shares of APTARGROUP, INC. (ATR) at an average of $136.26 ($136.23–$137.10, $0.48M total) across 2 trades on 2026-08-04.
1 min readTanda Stephan B. (President and CEO) sold 9,838 shares of APTARGROUP, INC. (ATR) at $136.16 ($1.34M total) on 2026-08-03.
2 min readTlili Hedi (Segment President) sold 8,854 shares of APTARGROUP, INC. (ATR) at $135.00 ($1.20M total) on 2026-08-03.
1 min readAPTARGROUP, INC. (ATR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atr-20260630x8kexx991.htm EX-99.1 Document Exhibit 99.1 Aptar Reports Second Quarter 2026 Results Crystal Lake, Illinois, July 30, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing,
6 min readAptar Pharma said the UK MHRA issued a Certificate of Good Manufacturing Practice compliance after inspecting its Nanopharm facility in Wales. The inspection found no critical observations and confirmed GMP compliance for Nanopharm’s cGMP analytical testing for orally inhaled and nasal drug products. Aptar said this expands regulated analytical services for customers across the product lifecycle.
3 min readATR said it saw temporary demand softness, with 14 orders since the start of 2026 and slower advanced discussions, but no cancellations and activity is picking up. ATR targets 50 firm orders as in 2025 or higher, at least 20% production growth over 2025, and 60+ deliveries by 2029, despite 2025 deliveries of 32 vs a 40 target.
6 min readBank of America named preferred packaging and paper stocks, citing pricing strength, volume growth, and strong cash flow. It rates Packaging Corp. of America (PKG) Buy with a $263 target, Crown Holdings (CCK) Buy at $145, Silgan (SLGN) Buy at $58, AptarGroup (ATR) Buy at $173, Ball (BALL) Buy at $73, and Avery Dennison (AVY) Buy at $210, citing upside versus recent prices.
5 min readATR said it saw softer customer discussions tied to uncertainty from the Iran war, with 14 orders since the start of the year and fewer advanced talks in H1. ATR reported no cancellations and expects order activity to accelerate in H2, targeting 50 firm orders in 2025 and at least 20% production growth. It delivered 32 aircraft in 2025 vs a 40 target.
5 min readPrieur Marc (Segment President) sold 5,000 shares of APTARGROUP, INC. (ATR) at an average of $115.58 ($115.53–$116.08, $0.58M total) across 2 trades on 2026-06-09.
1 min read
